These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 31669513)
1. A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis. Liu L; Shurin MR; Wheeler SE Clin Biochem; 2020 Jan; 75():40-47. PubMed ID: 31669513 [TBL] [Abstract][Full Text] [Related]
2. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring. Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341 [TBL] [Abstract][Full Text] [Related]
3. Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab. Tang F; Malek E; Math S; Schmotzer CL; Beck RC Am J Clin Pathol; 2018 Jul; 150(2):121-129. PubMed ID: 29901687 [TBL] [Abstract][Full Text] [Related]
4. Pilot Verification of a Novel Approach to Remove Electrophoretic Interference of the Therapeutic Monoclonal Antibody Daratumumab. Baloda V; Shurin MR; Wheeler SE J Appl Lab Med; 2022 Jun; 7(4):910-915. PubMed ID: 35060610 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. Sherbenou DW; Mark TM; Forsberg P Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795 [TBL] [Abstract][Full Text] [Related]
6. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab. Afifi S; Michael A; Lesokhin A Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916 [TBL] [Abstract][Full Text] [Related]
8. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079 [TBL] [Abstract][Full Text] [Related]
9. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S J Oncol Pract; 2018 Jul; 14(7):414-422. PubMed ID: 29996069 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114 [TBL] [Abstract][Full Text] [Related]
11. Electrophoretic patterns post daratumumab. Sheldon J; Wheeler RD; Powles R Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184 [TBL] [Abstract][Full Text] [Related]
12. Clearing drug interferences in myeloma treatment using mass spectrometry. Kohlhagen MC; Mills JR; Willrich MAV; Dasari S; Dispenzieri A; Murray DL Clin Biochem; 2021 Jun; 92():61-66. PubMed ID: 33691184 [TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113 [TBL] [Abstract][Full Text] [Related]
14. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873 [TBL] [Abstract][Full Text] [Related]
15. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab. Jimenez A; Scholl AR; Wang B; Schilke M; Carlsen ED Clin Biochem; 2024 May; 127-128():110761. PubMed ID: 38565341 [TBL] [Abstract][Full Text] [Related]
16. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637 [TBL] [Abstract][Full Text] [Related]
17. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies. Zajec M; Jacobs JFM; Groenen PJTA; de Kat Angelino CM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM J Proteome Res; 2018 Mar; 17(3):1326-1333. PubMed ID: 29424538 [TBL] [Abstract][Full Text] [Related]
18. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Mills JR; Kohlhagen MC; Willrich MAV; Kourelis T; Dispenzieri A; Murray DL Blood; 2018 Aug; 132(6):670-672. PubMed ID: 29891533 [No Abstract] [Full Text] [Related]
19. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Hoylman E; Brown A; Perissinotti AJ; Marini BL; Pianko M; Ye JC; Campagnaro E; Nachar VR Leuk Lymphoma; 2020 Mar; 61(3):691-698. PubMed ID: 31739729 [TBL] [Abstract][Full Text] [Related]
20. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Murata K; McCash SI; Carroll B; Lesokhin AM; Hassoun H; Lendvai N; Korde NS; Mailankody S; Landau HJ; Koehne G; Chung DJ; Giralt SA; Ramanathan LV; Landgren O Clin Biochem; 2018 Jan; 51():66-71. PubMed ID: 27664535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]